<DOC>
	<DOC>NCT00057356</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure.</brief_summary>
	<brief_title>Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Patients may be male or female age 18 years or older. Women must be postmenopausal or surgically sterile. Patients must have chronic heart failure of at least 2 months duration and be hospitalized for the treatment of worsening heart failure. The primary manifestation of worsening heart failure must be worsening dyspnea.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>YM078</keyword>
</DOC>